Markus Blocher

Markus Blocher

CEO Switzerland

Markus Blocher is the majority owner and CEO of Dottikon, a company specializing in the production of chemical substances for the pharmaceutical industry. He is recognized for his pragmatic management style, particularly during the company's significant investment program aimed at expanding production capacity.

Global Media Ratings
Dominance
0.00%
Persistence
1 wks
Reach
17,247
Power
1,395$
Sentiment
5.50
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Switzerland 2 5.50 0.18% +10% 8,654,622 17,247 $700,000 1,395$
Totals 2 8,654,622 17,247 $700,000 1,395$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Switzerland Switzerland: Markus Blocher expressed skepticism about the optimistic timelines for construction projects in the American pharmaceutical industry. 5

Neue Zürcher Zeitung: Investitionszusagen steigen auf fast 400 Milliarden

Switzerland Switzerland: Markus Blocher resolved issues with the construction of Dottikon ES's new production facility in a decisive manner. 7

Neue Zürcher Zeitung: Bachem und Dottikon ES: Die Erntezeit steht an

Switzerland Switzerland: Markus Blocher is the President, CEO, and majority shareholder of Dottikon ES, acknowledging his competitive advantage. 6

Neue Zürcher Zeitung: Kunden setzen Schweizer Pharmahersteller wegen Zöllen unter Druck

Switzerland Switzerland: Markus Blocher is the CEO and majority shareholder of Dottikon ES, a pharmaceutical supplier in Switzerland. 8

Neue Zürcher Zeitung: Markus Blocher will trotz Zollrisiken von US-Fabrik nichts wissen

Switzerland Switzerland: Markus Blocher, the chairman and majority shareholder, mentioned he cannot yet say if he will make his decision public. 5

Neue Zürcher Zeitung: Roche und Novartis sollen mehr Medikamente in den USA produzieren

Switzerland Switzerland: Markus Blocher is mentioned as the owner of Dottikon ES, a company that supplies its customers exclusively from Switzerland. 5

Neue Zürcher Zeitung: US-Zölle bedrohen das Geschäftsmodell der Schweizer Pharmabranche